{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:50:40Z","timestamp":1760014240733},"reference-count":39,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            A number of cases of both methicillin-susceptible\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Staphylococcus aureus<\/jats:named-content>\n            (MSSA) and methicillin-resistant\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. aureus<\/jats:named-content>\n            (MRSA) strains that have developed daptomycin resistance (DAP-R) have been reported. Telavancin (TLV) is a lipoglycopeptide agent with a dual mechanism of activity (cell wall synthesis inhibition plus depolarization of the bacterial cell membrane). Five recent daptomycin-susceptible (DAP-S)\/DAP-R MRSA isogenic strain pairs were evaluated for\n            <jats:italic>in vitro<\/jats:italic>\n            TLV susceptibility. All five DAP-R strains (DAP MICs ranging from 2 to 4 \u03bcg\/ml) were susceptible to TLV (MICs of \u22640.38 \u03bcg\/ml).\n            <jats:italic>In vitro<\/jats:italic>\n            time-kill analyses also revealed that several TLV concentrations (1-, 2-, and 4-fold MICs) caused rapid killing against the DAP-R strains. Moreover, for 3 of 5 DAP-R strains (REF2145, A215, and B\n            <jats:sub>2.0<\/jats:sub>\n            ), supra-MICs of TLV were effective at preventing regrowth at 24 h of incubation. Further, the combination of TLV plus oxacillin (at 0.25\u00d7 or 0.50\u00d7 MIC for each agent) increased killing of DAP-R MRSA strains REF2145 and A215 at 24 h (\u223c2-log and 5-log reductions versus TLV and oxacillin alone, respectively). Finally, using a rabbit model of aortic valve endocarditis caused by DAP-R strain REF2145, TLV therapy produced a mean reduction of &gt;4.5 log\n            <jats:sub>10<\/jats:sub>\n            CFU\/g in vegetations, kidneys, and spleen compared to untreated or DAP-treated rabbits. Moreover, TLV-treated rabbits had a significantly higher percentage of sterile tissue cultures (87% in vegetations and 100% in kidney and spleen) than all other treatment groups (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.0001). Together, these results demonstrate that TLV has potent bactericidal activity\n            <jats:italic>in vitro<\/jats:italic>\n            and\n            <jats:italic>in vivo<\/jats:italic>\n            against DAP-R MRSA isolates.\n          <\/jats:p>","DOI":"10.1128\/aac.00922-12","type":"journal-article","created":{"date-parts":[[2012,8,14]],"date-time":"2012-08-14T02:34:33Z","timestamp":1344911673000},"page":"5528-5533","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":20,"title":["Telavancin in Therapy of Experimental Aortic Valve Endocarditis in Rabbits Due to Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus"],"prefix":"10.1128","volume":"56","author":[{"given":"Yan Q.","family":"Xiong","sequence":"first","affiliation":[{"name":"Los Angeles Biomedical Research Institute, Torrance, California, USA"},{"name":"David Geffen School of Medicine at UCLA, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wessam Abdel","family":"Hady","sequence":"additional","affiliation":[{"name":"Los Angeles Biomedical Research Institute, Torrance, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold S.","family":"Bayer","sequence":"additional","affiliation":[{"name":"Los Angeles Biomedical Research Institute, Torrance, California, USA"},{"name":"David Geffen School of Medicine at UCLA, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[{"name":"Public Health Research Institute Tuberculosis Center, University of Medicine and Dentistry of New Jersey, Newark, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry N.","family":"Kreiswirth","sequence":"additional","affiliation":[{"name":"Public Health Research Institute Tuberculosis Center, University of Medicine and Dentistry of New Jersey, Newark, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-Jin","family":"Yang","sequence":"additional","affiliation":[{"name":"Los Angeles Biomedical Research Institute, Torrance, California, USA"},{"name":"David Geffen School of Medicine at UCLA, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/520655"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01307-08"},{"key":"e_1_3_2_4_2","volume-title":"CLSI M100-S15.","author":"Clinical and Laboratory Standards Institute","year":"2005","unstructured":"Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing; 15th informational supplement. CLSI M100-S15. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01101-08"},{"key":"e_1_3_2_6_2","first-page":"330","volume-title":"Antibiotics in laboratory medicine","author":"Eliopoulos GM","year":"1996","unstructured":"EliopoulosGM MoelleringRCJr. 1996. Antimicrobial combinations, p 330\u2013396. In LorianV (ed), Antibiotics in laboratory medicine, 4th ed. Williams & Wilkins, Baltimore, MD.","edition":"4"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.10.5285-5287.2005"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.1127-1134.2005"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.4.685"},{"key":"e_1_3_2_10_2","first-page":"87","article-title":"Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections","volume":"4","author":"Jafari Saraf L","year":"2011","unstructured":"Jafari SarafL WilsonES. 2011. Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections. Infect. Drug Resist. 4:87\u201395.","journal-title":"Infect. Drug Resist."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00719-07"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr234"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00559-07"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.05.030"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00742-09"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01398-07"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01544-08"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir034"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01710-08"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3163-3165.2005"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl256"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2011.09.023"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01266-06"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01682-08"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.2008\/000588-0"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00202-07"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.2871-2875.2004"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm170"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.5.1714-1718.2003"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.44.2.655-656.2006"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05849-11"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1086\/595740"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.12.8033-8038.2005"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1086\/429692"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00678-06"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.7.1737"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1086\/595738"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00122-10"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00487-10"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01415-08"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00922-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00922-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:59:14Z","timestamp":1645480754000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00922-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1128\/AAC.00922-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.00922-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"2012-05-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-08-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-10-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}